IN2014DN10404A - - Google Patents

Download PDF

Info

Publication number
IN2014DN10404A
IN2014DN10404A IN10404DEN2014A IN2014DN10404A IN 2014DN10404 A IN2014DN10404 A IN 2014DN10404A IN 10404DEN2014 A IN10404DEN2014 A IN 10404DEN2014A IN 2014DN10404 A IN2014DN10404 A IN 2014DN10404A
Authority
IN
India
Prior art keywords
pde7
addictions
phosphodiesterase
directed
disclosure
Prior art date
Application number
Other languages
English (en)
Inventor
Gregory A Demopulos
George A Gaitanaris
Roberto Ciccocioppo
Original Assignee
Omeros Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US13/835,607 external-priority patent/US9220715B2/en
Application filed by Omeros Corp filed Critical Omeros Corp
Publication of IN2014DN10404A publication Critical patent/IN2014DN10404A/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32Alcohol-abuse
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34Tobacco-abuse
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36Opioid-abuse
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Addiction (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
IN10404DEN2014 2012-05-07 2013-05-07 IN2014DN10404A (enExample)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261643611P 2012-05-07 2012-05-07
US13/835,607 US9220715B2 (en) 2010-11-08 2013-03-15 Treatment of addiction and impulse-control disorders using PDE7 inhibitors
PCT/US2013/039866 WO2013176877A2 (en) 2012-05-07 2013-05-07 Treatment of addiction and impulse-control disorders using pde7 inhibitors

Publications (1)

Publication Number Publication Date
IN2014DN10404A true IN2014DN10404A (enExample) 2015-08-14

Family

ID=49624481

Family Applications (1)

Application Number Title Priority Date Filing Date
IN10404DEN2014 IN2014DN10404A (enExample) 2012-05-07 2013-05-07

Country Status (10)

Country Link
EP (1) EP2846805B1 (enExample)
JP (1) JP2015521177A (enExample)
CN (3) CN114984229A (enExample)
AU (1) AU2013266793B2 (enExample)
CA (1) CA2871151C (enExample)
IN (1) IN2014DN10404A (enExample)
PL (1) PL2846805T3 (enExample)
RS (1) RS58381B1 (enExample)
SI (1) SI2846805T1 (enExample)
WO (1) WO2013176877A2 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9220715B2 (en) 2010-11-08 2015-12-29 Omeros Corporation Treatment of addiction and impulse-control disorders using PDE7 inhibitors
NZ628054A (en) 2010-11-08 2016-03-31 Omeros Corp Treatment of addiction and impulse-control disorders using pde7 inhibitors
RU2019108464A (ru) 2016-08-26 2020-09-28 Мицубиси Танабе Фарма Корпорейшн Бициклическое азотсодержащее гетероциклическое соединение
JPWO2023243659A1 (enExample) * 2022-06-15 2023-12-21
CN119894518A (zh) 2022-08-18 2025-04-25 米托迪治愈有限责任公司 取代的苯并噁唑和苯并呋喃化合物用于治疗和预防与慢性疲劳、筋疲力尽和/或劳累不耐受相关的疾病的用途

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4810426B2 (ja) * 2004-07-01 2011-11-09 第一三共株式会社 Pde7阻害作用を有するチエノピラゾール誘導体
US20060183763A1 (en) * 2004-12-31 2006-08-17 Pfizer Inc Novel pyrrolidyl derivatives of heteroaromatic compounds
RU2008116720A (ru) * 2005-09-26 2009-11-10 Эвиджен, Инк. (Us) Способы лечения наркозависимости и пагубных привычек в поведении
JP5580192B2 (ja) * 2007-03-27 2014-08-27 オメロス コーポレーション 運動障害の処置のためのpde7インヒビターの使用
US8637528B2 (en) * 2007-03-27 2014-01-28 Omeros Corporation Use of PDE7 inhibitors for the treatment of movement disorders
ES2438768T3 (es) * 2007-04-11 2014-01-20 Omeros Corporation Composiciones y métodos para la profilaxis y el tratamiento de adicciones
FR2943673B1 (fr) * 2009-03-27 2013-03-29 Sanofi Aventis Applications therapeutiques de derives de quinazolinedione
FR2944282B1 (fr) * 2009-04-09 2013-05-03 Sanofi Aventis Derives de quinazolinedione, leur preparation et leurs diverses applications therapeutiques
NZ628054A (en) * 2010-11-08 2016-03-31 Omeros Corp Treatment of addiction and impulse-control disorders using pde7 inhibitors

Also Published As

Publication number Publication date
RS58381B1 (sr) 2019-04-30
CA2871151A1 (en) 2013-11-28
CN104768556A (zh) 2015-07-08
EP2846805A4 (en) 2016-08-10
EP2846805B1 (en) 2018-11-21
JP2015521177A (ja) 2015-07-27
WO2013176877A3 (en) 2015-06-18
CN114984229A (zh) 2022-09-02
EP2846805A2 (en) 2015-03-18
CN112168972A (zh) 2021-01-05
AU2013266793B2 (en) 2016-08-04
SI2846805T1 (sl) 2019-04-30
WO2013176877A2 (en) 2013-11-28
CA2871151C (en) 2019-03-26
AU2013266793A1 (en) 2014-11-27
PL2846805T3 (pl) 2019-05-31

Similar Documents

Publication Publication Date Title
MX389018B (es) Tratamiento de trastornos de adiccion y control de impulsos usando inhibidores de pde7.
MX356525B (es) Vectores de virus asociados con adeno (aav) para uso en terapia de genes de coroideremia.
PL2825161T3 (pl) Inhibitory ludzkiej ezh2 i sposoby ich zastosowania
IL245042A0 (en) Treatment with proton tyrosine kinase inhibitors and immunotherapy
MX351464B (es) El uso de un agonista del receptor 8 tipo toll para el tratamiento de enfermedades alérgicas.
IL235846A0 (en) Nitrogen-substituted benzamides and their use for pain treatment
IN2014CN04014A (enExample)
MY181602A (en) Isochromene derivatives as phosphoinositide 3-kinases inhibitors
PH12015502302A1 (en) Treatment of allergic rhinitis using a combination of mometasone and olopatadine
PH12014500925A1 (en) Therapeutic combinations and methods of treating melanoma
IN2014DN10404A (enExample)
PL2780025T3 (pl) Zastosowanie ekstraktów z wiązówki (Filipendula) do leczenia i profilaktyki przewlekłych stanów bólowych
MX2013002121A (es) Quinolina-3-carboxamidas sustituidas como moduladores de kcnq2/3.
MX2016008150A (es) Formulaciones de berberina y usos de las mismas.
UA111520C2 (uk) [1,2,4]триазолопіридини і їх застосування як інгібіторів фосфодіестерази
MY200803A (en) Mpo inhibitors for use in medicine
MX2016005614A (es) Cuerpos de inclusion para el suministro transdermico de agentes terapeuticos y cosmeticos.
WO2012097121A9 (en) Specific nnos inhibitors for the therapy and prevention of human melanoma
ZA201600312B (en) Therapeutic agents for use in the prophylaxis and/or treatment of hyperkinetic movement disorders
CO7151515A2 (es) Métodos para tratar deficiencia en la marcha y/o equilibrio en pacientes con esclerosis múltiple que utilizan una aminopiridina
PL2790687T3 (pl) Modulatory trpc4 do stosowania w leczeniu lub zapobieganiu bólowi
PT2846805T (pt) Macrociclos peptidomiméticos
EP2934699A4 (en) PLOD2 GENE STIMULATORS AND USE OF SAID STIMULATORS FOR TREATING SKIN
MX2013006527A (es) Derivados de arilsulfonamida para la prevencion o el tratamiento de los trastornos oftalmologicos especificos.
AU2013101402A4 (en) Timber treatment formulations and methods of use